Showing results (121-130 of 253) with videos related to
Sort By:
Pageof 26
The Journal of Rheumatology|April 17, 2013
Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial programMichael E Weinblatt, Larry W Moreland, Rene Westhovens, et al.Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 28, 2020
Fatal COVID-19 in an MS patient on natalizumab: A case reportKathryn Rimmer, Rebecca Farber, Kiran Thakur, et al.Annals of Internal Medicine|June 21, 2006
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trialJoel M Kremer, Harry K Genant, Larry W Moreland, et al.Arthritis and Rheumatism|April 3, 2008
Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexateJoel M Kremer, Harry K Genant, Larry W Moreland, et al.Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|July 24, 2018
Pain and Catastrophizing in Patients With Rheumatoid Arthritis: An Observational Cohort StudyEzra M Cohen, Robert R Edwards, Clifton O Bingham, et al.International Journal of Pharmaceutics|June 5, 2016
Development of gellan gum containing formulations for transdermal drug delivery: Component evaluation and controlled drug release using temperature responsive nanogelsCarlos A Carmona-Moran, Oleksandra Zavgorodnya, Andrew D Penman, et al.Frontiers in Pharmacology|January 24, 2025
Duvelisib is a novel NFAT inhibitor that mitigates adalimumab-induced immunogenicityAboli Bhingarkar, Yuyin Wang, Keito Hoshitsuki, et al.Arthritis & Rheumatology (Hoboken, N.J.)|December 20, 2014
HLA-DRB1-associated rheumatoid arthritis risk at multiple levels in African Americans: hierarchical classification systems, amino acid positions, and residuesRichard J Reynolds, Altan F Ahmed, Maria I Danila, et al.Pharmacoepidemiology and Drug Safety|September 2, 2005
Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventionsDeborah Shatin, Nigel S B Rawson, Jeffrey R Curtis, et al.Arthritis and Rheumatism|July 30, 2005
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trialJoel M Kremer, Maxime Dougados, Paul Emery, et al.Pageof 26